/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. BiotechTV - News
  2. HCW 2026: Two key recent papers have validated the use of pramipexole in depression - Alto Neuro believes it has a combination therapy that can make it more tolerable and therefore even better
HCW 2026: Two key recent papers have validated the use of pramipexole in depression - Alto Neuro believes it has a combination therapy that can make it more tolerable and therefore even better

HCW 2026: Two key recent papers have validated the use of pramipexole in depression - Alto Neuro believes it has a combination therapy that can make it more tolerable and therefore even better

BiotechTV - News · Sep 14, 2026

Alto Neuro combines proven depression drug pramipexole with an antiemetic, aiming to unlock its high efficacy by solving its key tolerability issue.

Alto Neuro Makes an Effective Depression Drug Viable by Adding an Anti-Nausea Agent

Alto Neuro is commercializing pramipexole, a dopamine agonist with strong clinical data in depression, but poor tolerability due to nausea. By combining it with the antiemetic ondansetron, the company mitigates the key side effect holding the drug back from widespread use, unlocking its therapeutic potential.

HCW 2026: Two key recent papers have validated the use of pramipexole in depression - Alto Neuro believes it has a combination therapy that can make it more tolerable and therefore even better thumbnail

HCW 2026: Two key recent papers have validated the use of pramipexole in depression - Alto Neuro believes it has a combination therapy that can make it more tolerable and therefore even better

BiotechTV - News·2 months ago

Alto Neuro Targets Both Specialists and Primary Care with Parallel Adjunctive and Monotherapy Trials

To maximize market reach, Alto Neuro is simultaneously developing its lead drug as an add-on therapy for psychiatrists and as a standalone monotherapy for primary care physicians. This dual strategy caters to different prescriber behaviors and aims for broader, faster adoption upon approval by serving the full spectrum of patients and doctors.

HCW 2026: Two key recent papers have validated the use of pramipexole in depression - Alto Neuro believes it has a combination therapy that can make it more tolerable and therefore even better thumbnail

HCW 2026: Two key recent papers have validated the use of pramipexole in depression - Alto Neuro believes it has a combination therapy that can make it more tolerable and therefore even better

BiotechTV - News·2 months ago

Alto Neuro Accelerates FDA Path by Starting a Phase 3 Trial Before Phase 2b Data is Available

Leveraging strong existing academic data on its drug's core component, Alto Neuro is taking a calculated risk. By using recent financing to launch a Phase 3 study before its Phase 2b trial concludes, the company aims to compress its development timeline and submit its approval package to the FDA much sooner than a sequential approach would allow.

HCW 2026: Two key recent papers have validated the use of pramipexole in depression - Alto Neuro believes it has a combination therapy that can make it more tolerable and therefore even better thumbnail

HCW 2026: Two key recent papers have validated the use of pramipexole in depression - Alto Neuro believes it has a combination therapy that can make it more tolerable and therefore even better

BiotechTV - News·2 months ago